source
- Prime Medicine wins arbitration over gene-editing dispute with Beam, clearing path for AATD trialPrime Medicine announced it had prevailed in an arbitration against Beam Therapeutics, ending a dispute over gene-editing technology. The arbitrator determined that Prime’s work on a gene-editing…
- FDA approves Vera Therapeutics' Trutakna for IgA nephropathy, pricing set at $425,000 per yearThe U.S. Food and Drug Administration has granted approval to Trutakna, a new therapy from Vera Therapeutics, for the treatment of IgA nephropathy. IgA nephropathy is a kidney disorder where immun…